Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...
The centre, will initially focus on expanding Lilly's capabilities in automation, artificial intelligence, software product ...
Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...
The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...
Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and ...
Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the ...